“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a ...

Adult obesity rates in the United States dropped from 46% in 2022 to 45.6% in 2023, according to the new study published in ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

Some researchers believe that body fat percentage provides a more reliable indicator of the potential for obesity-related ... of men and women in the United States has been collected through ...

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why.

The study followed nearly 17 million people, the majority of whom were in the 26-75 age range, and found that after climbing ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

Discover the latest research findings on obesity in the United States, including a slight decrease in prevalence among adults in 2023. Learn more here.

For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why.